Scholarlink

<p>To investigate associations of serum CA 15–3 with interstitial lung disease (ILD), anti-PM/Scl100 antibodies, and other features in systemic sclerosis (SSc). We enrolled 59 SSc patients fulfilling 2013 ACR/EULAR criteria. CA 15–3 levels were compared between HRCT-confirmed ILD and non-ILD groups. Associations with autoantibodies, inflammation, patient-reported outcomes (PROs), and immunosuppressive therapy were assessed using nonparametric tests, ROC analysis, and multivariable logistic regression. Patients with ILD (n = 23) had significantly higher CA 15–3 levels (median 29.8 vs. 18.6 U/mL, p = 0.007). ROC analysis yielded an AUC of 0.72 (95% CI 0.62–0.81, p = 0.002). CA 15–3 remained independently associated with ILD (OR 1.05 per U/mL, 95% CI 1.01–1.10, p = 0.021). CA 15–3 was also higher in anti-PM/Scl100–positive patients (34.5 vs. 21.0 U/mL, p = 0.01). No associations were seen with other disease features, CRP, ESR, IL-6, or PROs. Serum CA 15–3 is independently associated with ILD in SSc and elevated in anti-PM/Scl100–positive patients. It may serve as an accessible biomarker of pulmonary involvement, pending validation in larger cohorts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Associations of serum CA 15–3 with interstitial lung disease, PM/Scl100 antibodies and other disease characteristics in systemic sclerosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月11日

查看全文
  • Jakub Trefler,
  • Anna Pasierb,
  • Lidia Lech,
  • Katarzyna Życińska

摘要

To investigate associations of serum CA 15–3 with interstitial lung disease (ILD), anti-PM/Scl100 antibodies, and other features in systemic sclerosis (SSc). We enrolled 59 SSc patients fulfilling 2013 ACR/EULAR criteria. CA 15–3 levels were compared between HRCT-confirmed ILD and non-ILD groups. Associations with autoantibodies, inflammation, patient-reported outcomes (PROs), and immunosuppressive therapy were assessed using nonparametric tests, ROC analysis, and multivariable logistic regression. Patients with ILD (n = 23) had significantly higher CA 15–3 levels (median 29.8 vs. 18.6 U/mL, p = 0.007). ROC analysis yielded an AUC of 0.72 (95% CI 0.62–0.81, p = 0.002). CA 15–3 remained independently associated with ILD (OR 1.05 per U/mL, 95% CI 1.01–1.10, p = 0.021). CA 15–3 was also higher in anti-PM/Scl100–positive patients (34.5 vs. 21.0 U/mL, p = 0.01). No associations were seen with other disease features, CRP, ESR, IL-6, or PROs. Serum CA 15–3 is independently associated with ILD in SSc and elevated in anti-PM/Scl100–positive patients. It may serve as an accessible biomarker of pulmonary involvement, pending validation in larger cohorts.